Premium
Tofacitinib Synthesis – An Asymmetric Challenge
Author(s) -
Carvalho Luísa C. R.,
Lourenço Ana,
Ferreira Luísa Maria,
Branco Paula Sério
Publication year - 2019
Publication title -
european journal of organic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 155
eISSN - 1099-0690
pISSN - 1434-193X
DOI - 10.1002/ejoc.201801180
Subject(s) - tofacitinib , chemistry , janus kinase , rheumatoid arthritis , piperidine , active ingredient , psoriatic arthritis , combinatorial chemistry , pharmacology , stereochemistry , chirality (physics) , janus kinase inhibitor , kinase , biochemistry , medicine , nambu–jona lasinio model , chiral symmetry breaking , physics , quantum mechanics , quark
Tofacitinib is a Janus activated kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis and active psoriatic arthritis. Its synthesis normally involves long synthetic sequences due to the chirality associated to the piperidine ring. This review is a comprehensive analysis of the different synthetic methods used to prepare this active pharmaceutical ingredient (API), covering the related journal and patent literature.